Literature DB >> 17646223

Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes.

Donald A Mahler1, Laurie A Waterman, Joseph Ward, Corliss McCusker, Richard ZuWallack, John C Baird.   

Abstract

BACKGROUND: Numerous instruments have been developed to examine the impact of activities on breathlessness. The primary purpose of this study was to examine the validity and responsiveness of the self-administered computerized (SAC) versions of the multidimensional baseline dyspnea index (BDI) and the transition dyspnea index (TDI).
METHODS: Sixty-five patients with COPD who complained of exertional breathlessness were evaluated at an initial visit and after receiving standard therapy at two academic medical centers. Dyspnea scores from the SAC versions were compared with those obtained with the Medical Research Council (MRC) scale and with the original interview versions of the BDI and TDI.
RESULTS: At the initial visit, all three dyspnea instruments showed similar correlations among themselves and with lung function. At the follow-up visit (mean [+/- SD] time after initial visit, 48 +/- 16 days), breathlessness scores were improved on all three instruments. Correlations were consistently higher for both versions of the TDI, and changes in lung function compared with corresponding values for DeltaMRC scale. Although 55% of patients reported no change in breathlessness on the MRC scale following treatment, the mean SAC and interview TDI scores were increased by 1.0 +/- 2.4 and 1.4 +/- 2.5, respectively, in these same patients.
CONCLUSIONS: Both versions of the BDI and the MRC scale showed concurrent validity at the initial visit. The SAC TDI demonstrated responsiveness to standard therapy that was comparable with the findings of the interview TDI, but was better than that recorded with the MRC scale. The advantages of the SAC TDI include a patient-reported score on a continuous scale using computer technology.

Entities:  

Mesh:

Year:  2007        PMID: 17646223     DOI: 10.1378/chest.07-0703

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

1.  Design of the Redefining Therapy in Early COPD Study.

Authors:  MeiLan K Han; Wen Ye; Dong-Yun Kim; Prescott Woodruff
Journal:  Chronic Obstr Pulm Dis       Date:  2020-10

2.  An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.

Authors:  M S Kavuru; A Malur; I Marshall; B P Barna; M Meziane; I Huizar; H Dalrymple; R Karnekar; M J Thomassen
Journal:  Eur Respir J       Date:  2011-04-08       Impact factor: 16.671

3.  GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.

Authors:  MeiLan K Han; Hana Muellerova; Douglas Curran-Everett; Mark T Dransfield; George R Washko; Elizabeth A Regan; Russell P Bowler; Terri H Beaty; John E Hokanson; David A Lynch; Paul W Jones; Antonio Anzueto; Fernando J Martinez; James D Crapo; Edwin K Silverman; Barry J Make
Journal:  Lancet Respir Med       Date:  2012-09-03       Impact factor: 30.700

4.  Patient-reported dyspnea in COPD reliability and association with stage of disease.

Authors:  Donald A Mahler; Joseph Ward; Laurie A Waterman; Corliss McCusker; Richard ZuWallack; John C Baird
Journal:  Chest       Date:  2009-08-20       Impact factor: 9.410

5.  Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease.

Authors:  Thierry Perez; Pierre Régis Burgel; Jean-Louis Paillasseur; Denis Caillaud; Gaetan Deslée; Pascal Chanez; Nicolas Roche
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-08-18

Review 6.  Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management.

Authors:  Dave Singh; Marc Miravitlles; Claus Vogelmeier
Journal:  Adv Ther       Date:  2016-12-15       Impact factor: 3.845

7.  Analysis of longitudinal changes in dyspnea of patients with chronic obstructive pulmonary disease: an observational study.

Authors:  Toru Oga; Mitsuhiro Tsukino; Takashi Hajiro; Akihiko Ikeda; Koichi Nishimura
Journal:  Respir Res       Date:  2012-09-25

Review 8.  Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement.

Authors:  Paul Jones; Marc Miravitlles; Thys van der Molen; Karoly Kulich
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-10-16

9.  Taking Healthy Steps: rationale, design and baseline characteristics of a randomized trial of a pedometer-based Internet-mediated walking program in veterans with chronic obstructive pulmonary disease.

Authors:  Carlos H Martinez; Marilyn L Moy; Huong Q Nguyen; Miriam Cohen; Reema Kadri; Pia Roman; Robert G Holleman; Hyungjin Myra Kim; David E Goodrich; Nicholas D Giardino; Caroline R Richardson
Journal:  BMC Pulm Med       Date:  2014-02-03       Impact factor: 3.317

10.  Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Authors:  Claus F Vogelmeier; Mina Gaga; Maryam Aalamian-Mattheis; Timm Greulich; Jose M Marin; Walter Castellani; Vincent Ninane; Stephen Lane; Xavier Nunez; Francesco Patalano; Andreas Clemens; Konstantinos Kostikas
Journal:  Respir Res       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.